Australia markets closed

AcelRx Pharmaceuticals Inc (R5XA.MU)

Munich - Munich Delayed price. Currency in EUR
Add to watchlist
0.8510+0.0850 (+11.10%)
As of 08:02AM CEST. Market open.
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Cash flows from operating activities
Net income
-14,199
-18,397
47,755
-35,099
-40,379
Depreciation & amortisation
49
311
1,647
1,973
1,853
Stock-based compensation
1,462
1,729
2,889
4,609
4,424
Change in working capital
-2,668
-1,541
-1,390
203
-2,288
Accounts receivable
-
-189
-149
475
-203
Inventory
0
61
-107
-295
957
Accounts payable
-737
-575
551
111
1,016
Other working capital
-15,125
-17,592
-28,695
-31,829
-40,360
Other non-cash items
-608
-1,792
-84,955
-2,498
-2,827
Net cash provided by operating activities
-15,125
-17,492
-28,331
-30,002
-38,505
Cash flows from investing activities
Investments in property, plant and equipment
-
-100
-364
-1,827
-1,855
Purchases of investments
-7,881
-3,651
-7,861
-70,459
-44,611
Sales/maturities of investments
1,500
500
46,362
46,984
80,605
Other investing activities
-
2,723
-1,687
-821
-
Net cash used for investing activities
-3,658
-528
36,450
-26,123
34,139
Cash flows from financing activities
Debt repayment
-3,333
-5,416
-8,433
-8,833
-4,667
Common stock issued
-
8,856
7,986
50,278
21,337
Common stock repurchased
-
0
-315
0
-
Other financing activities
-
-22
-58
-249
-86
Net cash used provided by (used for) financing activities
17,552
3,466
-507
41,514
16,956
Net change in cash
-1,231
-14,554
7,612
-14,611
12,590
Cash at beginning of period
13,353
20,275
12,663
27,274
14,684
Cash at end of period
12,122
5,721
20,275
12,663
27,274
Free cash flow
Operating cash flow
-15,125
-17,492
-28,331
-30,002
-38,505
Capital expenditure
-
-100
-364
-1,827
-1,855
Free cash flow
-15,125
-17,592
-28,695
-31,829
-40,360